In B‐ALL, one study demonstrated high and subtype‐specific expression of IGF2BP3 associated with good outcomes in high‐risk patients, suggesting that IGF2BP3 could improve stratification and prognosis of B‐ALL [134]. Here, IGF2BP3 is linked to acute lymphoblastic leukemia.